Nasdaq Welcomes TiGenix NV (Nasdaq: TIG) to The Nasdaq Stock Market

NEW YORK, Dec. 15, 2016 -- The Nasdaq Stock Market today announces the first day of trading for TiGenix NV (Nasdaq:TIG) (TiGenix), a Belgium based biopharmaceutical company. To commemorate its initial public offering in the United States, the Company visited the Nasdaq MarketSite in Times Square for the closing bell ceremony.

TiGenix NV (Nasdaq:TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, visits the Nasdaq MarketSite in Times Square in celebration of its initial public offering.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/77d1f649-5be1-456c-bca6-b95f8382b5b8

TiGenix develops and commercializes novel therapeutics from its proprietary technology platforms of allogeneic, or donor-derived, stem cells. The Company’s lead product candidate, Cx601 is in registration with the European Medicines Agency for the treatment of complex perianal fistulas in Crohn’s disease patients. Earlier this year, TiGenix entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. The Company anticipates initiating a Phase III trial to register Cx601 in the United States during the first six months of 2017.

“Being listed on Nasdaq is a significant milestone for TiGenix. We look forward to being a part of the U.S. markets and initiating our Phase III plans for Cx601 in the U.S. and further developing our product platforms for other disease opportunities,” said Eduardo Bravo, Managing Director & Chief Executive Officer, TiGenix.

“Nasdaq is excited to include TiGenix in our family of leading and disruptive biopharmaceutical companies,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq. “The Company’s history of developing innovative and safe treatment options for a broad range of inflammatory and autoimmune diseases speaks to the core value of Nasdaq. We are truly proud that TiGenix chose Nasdaq as their listing partner as they continue to advance with their clinical development and global commercialization of their products.”

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq.  Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com

- NDAQG -

Media Relations Contacts:
Stephanie Lowenthal
(646) 441-5073
[email protected]

Emily Pan
(646) 441-5120
[email protected]